Table 3. KEGG analysis of MDS-related patients.
| Term description | Observed gene count | FDR | Matching proteins in your network (labels) |
|---|---|---|---|
| KEGG analysis of MDS patients | |||
| CML | 5 | 8.86E–07 | CBL, KRAS, NRAS, RUNX1, TP53 |
| AML | 4 | 2.1E–05 | CEBPA, KRAS, NRAS, RUNX1 |
| Central carbon metabolism in cancer | 4 | 2.1E–05 | IDH1, KRAS, NRAS, TP53 |
| Pathways in cancer | 6 | 0.00012 | CBL, CEBPA, KRAS, NRAS, RUNX1, TP53 |
| Thyroid cancer | 3 | 0.00013 | KRAS, NRAS, TP53 |
| Bladder cancer | 3 | 0.00014 | KRAS, NRAS, TP53 |
| MicroRNAs in cancer | 4 | 0.00015 | DNMT3A, KRAS, NRAS, TP53 |
| Transcriptional misregulation in cancer | 4 | 0.00021 | CEBPA, ETV6, RUNX1, TP53 |
| Endometrial cancer | 3 | 0.00025 | KRAS, NRAS, TP53 |
| Mitophagy—animal | 3 | 0.00029 | KRAS, NRAS, TP53 |
| KEGG analysis of suspected MDS patients | |||
| CML | 3 | 0.00048 | CBL, RUNX1, TP53 |
| Central carbon metabolism in cancer | 2 | 0.0163 | IDH1, TP53 |
| Pathways in cancer | 3 | 0.041 | CBL, RUNX1, TP53 |
| MicroRNAs in cancer | 2 | 0.041 | DNMT3A, TP53 |
| Herpes simplex infection | 2 | 0.0417 | SRSF2, TP53 |
| Transcriptional misregulation in cancer | 2 | 0.0417 | RUNX1, TP53 |
| Proteoglycans in cancer | 2 | 0.0417 | CBL, TP53 |
| CML | 3 | 0.00048 | CBL, RUNX1, TP53 |
| Central carbon metabolism in cancer | 2 | 0.0163 | IDH1, TP53 |
| Pathways in cancer | 3 | 0.041 | CBL, RUNX1, TP53 |
| KEGG analysis of MDS transformation-related patients | |||
| Transcriptional misregulation in cancer | 3 | 0.00058 | CEBPA, ETV6, RUNX1 |
| AML | 2 | 0.0026 | CEBPA, RUNX1 |
KEGG, Kyoto Encyclopedia of Genes and Genomes; MDS, myelodysplastic syndrome; FDR, false discovery rate; CML, chronic myeloid leukemia; AML, acute myeloid leukemia.